Clinical Trials in China / NCT05634057
Recruiting
Not applicable
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
NCT05634057 · tracked via the Priya Life Science China tracker
Condition(s) studied
Sepsis
Investigational drug(s) / intervention(s)
Anisodamine hydrobromide combined with heparin: The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
Study summary
The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of patients with critical infection, in the hope that the therapy will provide alternatives to the treatment of patients with critical infection.
Eligibility
Inclusion criteria:
1. Age greater than 18 years;
2. Meets the diagnostic criteria for sepsis according to the "Sepsis-3" ;
3. Patient or their legal representative consents to treatment and signs an informed consent form.
Exclusion criteria:
1. Patients expected to die within 24 hours after enrollment;
2. Contraindications to low molecular weight heparin and scopolamine butylbromide drugs;
3. Patients with thrombotic diseases requiring treatment with low molecular weight heparin;
4. Patients with terminal-stage malignancies, severe immunodeficiency, immunosuppression, severe liver or kidney dysfunction (defined as liver or kidney SOFA score ≥ 3 points), etc.;
5. Pregnant and lactating women;
6. Patients participating in other clinical trials.
Primary outcome measure(s)
- 28-day mortality — Every patients' survival time will be observed on day 28 after admission.
The patients will be followed up for 28 days, as our usual hospital length of stay for critically infected patients is 28 days. The investigators will recorded the specific time of death.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Beijing Chaoyang Hospital, Capital Medical University | Beijing | China | Recruiting |
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05634057 on ClinicalTrials.gov ↗ ← All trials in China